2 news items
Autolus Therapeutics Reports First Quarter 2024 Financial Results and Business Updates
AUTL
17 May 24
product candidate for multiple myeloma which comprises two independent CARs for the multiple myeloma targets, BCMA and CD19. We have developed an optimized
Autolus Therapeutics Reports Full Year 2023 Financial Results and Business Updates
AUTL
14 Mar 24
independent CARs for the multiple myeloma targets, BCMA and CD19. We have developed an optimized BCMA CAR designed for improved killing of target cells
- Prev
- 1
- Next